Disappointing Results of a Phase II Trial Using Angiogenesis Inhibitor
That’s the question researchers hoped to answer in a phase II double-blind trial comparing mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus…
Adaptive Pre-Surgery Therapy for Patients with Localized Pancreatic Cancer
Will a flexible approach to neoadjuvant treatment work better for pancreatic cancer patients with tumors that can be removed surgically?
The Pancreatic Standard of Care is No Longer So Standard
Do you want to understand more about how your doctor chooses your treatments? Learn about the standard of care for pancreatic cancer.
Adding Focused Radiation to Standard Pancreatic Cancer Treatment
Researchers are using IORT--intraoperative radiation therapy--to treat pancreatic cancer that cannot be surgically removed.
Standard Chemotherapy Plus Novel Drugs for Advanced Pancreatic Cancer
This trial tests the effectiveness of three different novel drugs, including immunotherapy, added to standard treatment for advanced pancreatic cancer.
COMBATing Pancreatic Cancer
Dr. Manuel Hidalgo explains the COMBAT trial, which combines immunotherapy, a checkpoint inhibitor, and chemotherapy to attack pancreatic cancer.
Targeting Cancer-Associated Wasting With Experimental Immunotherapy
Wasting, or cachexia, is the focus of a clinical trial testing a cachexia immunotherapy treatment combined with standard pancreatic cancer treatment.
A PARP Inhibitor Approval for Pancreatic Cancer
PARP inhibitors, a type of targeted therapy, are being studied as treatment for pancreatic cancer in a number of clinical trials.
Pancreatic Cancer: 2018 Highlights And Looking Forward to 2019
Dr. Allyson Ocean leads an overview of the new treatments and protocol from 2018 as well as what are the next steps in treatment for 2019.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Due to numerous factors, including rising rates of obesity and smoking, for example, pancreatic cancer jumped to number three, and…